Christian Eberly

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “PARP1 PARylates and stabilizes STAT5 in FLT3-ITD acute myeloid leukemia and other STAT5-activated cancers”.

PARP1 PARylates and stabilizes STAT5 in FLT3-ITD acute myeloid leukemia and other STAT5-activated cancers

Translational Oncology(2021)10.1016/j.tranon.2021.101283

N/A

0DataRank · unranked

14 citations

Rachel Abbotts, Christian Eberly, Mariusz Karbowski, Maria R. Baer, Tami J. Kingsbury +2 more

Activating STING1-dependent immune signaling in TP53 mutant and wild-type acute myeloid leukemia

Proceedings of the National Academy of Sciences(2022)10.1073/pnas.2123227119

N/A

0DataRank · unranked

22 citations

Michael J. Topper, Anna J. Dellomo, Lora Stojanovic, Lena J. McLaughlin, T. Michael Creed +7 more

The polypharmacy combination of the BCL-2 inhibitor venetoclax (VEN) and the FLT3 inhibitor gilteritinib (GIL) is more active in acute myeloid leukemia cells than novel polypharmacologic BCL-2/FLT3 VEN–GIL hybrid single-molecule inhibitors

European Journal of Medicinal Chemistry(2024)10.1016/j.ejmech.2024.117190

N/A

0DataRank · unranked

7 citations

Christian Eberly, Alexandria M. Chan, Minjung Kim, Brandon D. Lowe, Curt I. Civin +2 more

Augmenting the Anti‐Leukemic Activity of the BCL‐2 Inhibitor Venetoclax Through Its Transformation Into Polypharmacologic Dual BCL‐2/HDAC1 and Dual BCL‐2/HDAC6 Inhibitors

Drug Development Research(2025)10.1002/ddr.70084

N/A

0DataRank · unranked

5 citations

Christian Eberly, Brandon Drennen, Christopher C. Goodis, Zoe Wuyts, Curt I. Civin +2 more